Parkinson's disease antisense gene therapy - Thomas Jefferson University

Drug Profile

Parkinson's disease antisense gene therapy - Thomas Jefferson University

Alternative Names: Antisense GAD65+GAD67 gene therapy; Antisense GAD67 gene therapy

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thomas Jefferson University
  • Class Gene therapies
  • Mechanism of Action GABA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
  • 17 Jun 2003 Preclinical trials in Parkinson's disease in USA (unspecified route)
  • 17 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Gene Therapies and Parkinson's Disease and Movement Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top